User login
Enter your username and password here in order to log in on the website:
Keywords
- ABPA_Aspergillus
- accompanying diseases
- air-improving devices
- allergy
- animals_pets
- antibiotic therapy
- asthma
- complementary medicine
- covid-19
- diabetes
- diagnostics
- drugs side effects
- drugs under development_genetic therapy
- ENT
- general aspects
- genetics
- health care
- hepatobiliary disease
- hygiene
- i.v.-lines
- inhalation
- lung
- microbiology
- miscellaneous
- modulator therapy
- MRSA
- nutrition and GI problems
- oxygen supplementation_therapy
- physiotherapy
- Pseudomonas aeruginosa
- psychosocial
- public facilities
- recreational activities
- reproduction
- research
- social law
- sport
- swine flu_novel influenza
- transplantation
- travelling
- vaccination
- ventilation
Topics
- QR-10
- Hello Which mutations are concerned by the QR-10 molecule which targets the correct synthesis of CFTR protein? Thank you for your reply
- 25.07.2016
- CTP-656 POTENTIATOR
- Hello Could you tell us which company produces the activator CTP-656 and which patients will potentially benefit from this molecule? Thank you for your reply
- 25.07.2016
- Meveol®
- Dear expert team, I read something about the development of Meveol®. It seems to be very promising to me. Is there anything new at the moment about this topic? Can one make a prognosis, when the drug will be on the market? Many thanks in advance.
- 16.07.2016
- Mutations F508del and R553X
- Dear expert team, Our son has been diagnosed to suffer from CF at the beginning of January at the age of 9 weeks, after we had been admitted to hospital with a hemoglobin value of 6. The little boy became 2 blood transfusions and takes zinc tablets since then, as he also had a zinc deficiency. ...
- 24.06.2016
- GLPG1837 Galapagos clinical trial
- Hello A clinical trial with the CFTR protein potentiator GLPG1837 (Galapagos) has just started. Obviously this molecule is for patients carrying a class III mutation. Is the clinical trial ongoing in France? When will results be available? If compared to Kalydeco® could this new molecule ...
- 20.06.2016
- Glutathione
- Hello Could you please give us information regarding reduced Glutathione? Is there any deficiency for CF patients (that would be expected) ? Is this deficiency associated with some symptoms in particular? Is there any research done with external supply of Glutathione? What type of Glutathione? ...
- 06.06.2016
- Orkambi®
- Good evening, I have read the side effects of Orkambi®. What are the results of studies in countries that prescribe this treatment for a couple of years now (regarding these side effects)? Best wishes
- 13.05.2016
- MUTATION c.1680-886A>G (remainder)
- Hello, Thank you for your reply on the mutation c.1680-886A> G. It is therefore a splicing mutation and not a "nonsense" mutation. However, since due to reading frameshift it leads to a stop codon, can we assume that patients with this mutation would be eligibe to ataluren (PTC124)? Thank ...
- 11.05.2016
- Contraception in case of the intake of Orkambi® or the like
- My daughter (20 yrs) takes part in a Vertex study, the drug is similar to Orkambi®. For contraception, the pill and all other hormone-based devices, are not suitable. How can she do an effective contraception without being afraid of getting pregnant? The gynecologist has no understanding for her ...
- 25.04.2016
- Orkambi® Side Effects
- Good evening Do you have information on the side effects of this treatment (Orkambi®) available in France since shortly but already widely distributed in CANADA or the USA? The side effects are severe and there is little feedback to take a decision. Best regards
- 24.04.2016
